Genomic Health (GHDX) Tops Q1 EPS by 6c

Genomic Health (NASDAQ: GHDX) reported Q1 EPS of $0.34, $0.06 better than the analyst estimate of $0.28. Revenue for the quarter came in at $108.8 million versus the consensus estimate of $106.68 million.

• "We expect to achieve double-digit revenue growth for the year with continued growth across key products and look forward to the national reimbursement decision in Germany for the Oncotype DX breast cancer test."

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
• Pulmatrix (PULM) Reports Q2 Loss of $0.29